BEDMINSTER, N.J., Jan. 10, 2025 (WORLD NEWSWIRE)– Matinas BioPharma Holdings, Inc. MTNB reveals that on January 6, 2025, it got a NYSE American LLC notification suggesting that the Business has actually fallen listed below specific NYSE American continued listing requirements due to the fact that it stopped working to hold its yearly conference of shareholders for the ending on December 31, 2024, as stated in Area 704 of the NYSE American Business Guide.
The Business plans to hold its yearly conference no behind December 31, 2025 in order to gain back compliance under the NYSE American Business Guide.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical business concentrated on providing cutting-edge treatments utilizing its lipid nanocrystal (LNC) platform shipment innovation.
For additional information, please see www.matinasbiopharma.com.
Positive Declarations
This release includes “positive declarations” within the significance of the Personal Securities Lawsuits Reform Act of 1995, consisting of those associating with compliance with NYSE American listing requirements, and other declarations that are predictive in nature, that rely on or describe future occasions or conditions. All declarations besides declarations of historic reality are declarations that might be positive declarations. Positive declarations consist of words such as “anticipates,” “expects,” “plans,” “strategies,” “could,” “thinks,” “price quotes” and comparable expressions. These declarations include understood and unidentified dangers, unpredictabilities and other elements which might trigger real outcomes to be materially various from any future outcomes revealed or suggested by the positive declarations. Positive declarations go through a variety of dangers and unpredictabilities, consisting of, however not restricted to, the sale of MAT 2203, and the assessment of other options for the Business, consisting of a winddown or dissolution of the Business; and the other elements noted under “Threat Elements” in our filings with the SEC, consisting of Kinds 10-K, 10-Q and 8-K. Financiers are warned not to position unnecessary dependence on such positive declarations, which speak just since the date of this release. Other than as might be needed by law, the Business does not carry out any commitment to launch openly any modifications to such positive declarations to show occasions or situations after the date hereof or to show the event of unexpected occasions. Matinas BioPharma’s item prospects are all in an advancement phase and are not offered for sale or usage.
Financier Contact
Jerome D. Jabbour
Ceo
( 908) 484-8805
operations@matinasbiopharma.com
Market News and Data gave you by Benzinga APIs